{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T02:40:24Z","timestamp":1792982424960,"version":"4.5.0"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bcp.2026.118276","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:37:04Z","timestamp":1784590624000},"page":"118276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P1","title":["Beyond immune checkpoint blockade: T cell engagers and antibody-drug conjugates in cancer and autoimmune disease"],"prefix":"10.1016","volume":"253","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4747-8549","authenticated-orcid":false,"given":"Ahmed M.","family":"Abdelaziz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa M.","family":"Shokr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.118276_b0005","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01668","article-title":"The future of immunotherapy: a 20-year perspective","volume":"8","author":"Wraith","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118276_b0010","doi-asserted-by":"crossref","unstructured":"P. Garg, S. Pareek, P. Kulkarni, D. Horne, R. Salgia, S.S. Singhal, Next-generation immunotherapy: advancing clinical applications in cancer treatment, J. Clin. Med. 2024, 13 (2024) 6537, https:\/\/doi.org\/10.3390\/jcm13216537.","DOI":"10.3390\/jcm13216537"},{"key":"10.1016\/j.bcp.2026.118276_b0015","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1485303","article-title":"Efficacy and safety of PD-1\/PD-L1 and CTLA-4 immune checkpoint inhibitors in the treatment of advanced colorectal cancer: a systematic review and meta-analysis","volume":"15","author":"Song","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118276_b0020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1298571","article-title":"The role of immune checkpoints in antitumor response: a potential antitumor immunotherapy","volume":"14","author":"Mej\u00eda-Guarnizo","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118276_b0025","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/cei\/uxac089","article-title":"Genetics of immune dysregulation and cancer predisposition: two sides of the same coin","volume":"210","author":"Matza Porges","year":"2022","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.bcp.2026.118276_b0030","article-title":"Tumor\u2010associated macrophages as therapeutic targets: deciphering interaction networks and advancing clinical translation","volume":"7","author":"Bao","year":"2026","journal-title":"MedComm (Beijing)"},{"key":"10.1016\/j.bcp.2026.118276_b0035","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jare.2023.10.009","article-title":"Deciphering the role of CD47 in cancer immunotherapy","volume":"63","author":"Liu","year":"2023","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.bcp.2026.118276_b0040","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1111\/cas.13663","article-title":"CD47-signal regulatory protein \u03b1 signaling system and its application to cancer immunotherapy","volume":"109","author":"Murata","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bcp.2026.118276_b0045","first-page":"619","article-title":"Rituximab in the treatment of non-Hodgkin\u2019s lymphoma","volume":"2","author":"Hauptrock","year":"2008","journal-title":"Biologics"},{"key":"10.1016\/j.bcp.2026.118276_b0050","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.4049\/jimmunol.0713732","article-title":"M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro","volume":"182","author":"Leidi","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2026.118276_b0055","doi-asserted-by":"crossref","unstructured":"J. Xu, L. Ding, J. Mei, Y. Hu, X. Kong, S. Dai, T. Bu, Q. Xiao, K. Ding, Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments, Signal Transd. Targeted Therapy 2025 10:1 10 (2025) 268-. https:\/\/doi.org\/10.1038\/s41392-025-02325-5.","DOI":"10.1038\/s41392-025-02325-5"},{"key":"10.1016\/j.bcp.2026.118276_b0060","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1186\/s12916-025-04483-3","article-title":"Cross-speciality collaborative care in complex immune-mediated inflammatory diseases: treating the person living with the condition","volume":"23","author":"Taylor","year":"2025","journal-title":"BMC Med."},{"key":"10.1016\/j.bcp.2026.118276_b0065","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/mdr2.70018","article-title":"Global disease burden of immune\u2010mediated inflammatory diseases (IMIDs), 1990\u20132021","volume":"1","author":"Zhu","year":"2025","journal-title":"Med Research"},{"key":"10.1016\/j.bcp.2026.118276_b0070","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3390\/biom13050747","article-title":"A new generation of IMiDs as treatments for neuroinflammatory and neurodegenerative disorders","volume":"13","author":"Kopp","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.bcp.2026.118276_b0075","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10238-026-02057-y","article-title":"The safety and efficacy of bispecific T-cell engagers (TCEs) in patients with glioma","volume":"26","author":"Robat-Jazi","year":"2026","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.bcp.2026.118276_b0080","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1688057","article-title":"Antibody\u2013drug conjugate: a newly developed biological missile for tumor treatment","volume":"15","author":"Tang","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2026.118276_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2025.103497","article-title":"Immune mediated inflammatory disease: T cell engager versus antibody drug conjugate","volume":"157","author":"Liang","year":"2025","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.bcp.2026.118276_b0090","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40364-022-00373-5","article-title":"Targeting CD47\/SIRP\u03b1 as a therapeutic strategy, where we are and where we are headed","volume":"10","author":"Qu","year":"2022","journal-title":"Biomark. Res."},{"key":"10.1016\/j.bcp.2026.118276_b0095","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","article-title":"The CD47-SIRP\u03b1 immune checkpoint","volume":"52","author":"Logtenberg","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2026.118276_b0100","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2018.0217","article-title":"The macrophage checkpoint CD47: SIRPa for recognition of \u201cself\u201d cells: from clinical trials of blocking antibodies to mechanobiological fundamentals","volume":"374","author":"Andrechak","year":"2019","journal-title":"Philos. Trans. R. Soc., B"},{"key":"10.1016\/j.bcp.2026.118276_b0105","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9435030","article-title":"CD47-SIRP\u03b1 axis as a biomarker and therapeutic target in cancer: current perspectives and future challenges in nonsmall cell lung cancer","volume":"2020","author":"Catal\u00e1n","year":"2020","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.bcp.2026.118276_b0110","article-title":"Advances in anti-tumor treatments targeting the CD47\/SIRP\u03b1 axis","volume":"11","author":"Zhang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118276_b0115","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.coi.2009.01.008","article-title":"Signal regulatory protein alpha (SIRP\u03b1) \/ CD47 interaction and function","volume":"21","author":"Barclay","year":"2009","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.bcp.2026.118276_b0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127178","article-title":"Regulation of phagocyte migration by signal regulatory protein-alpha signaling","volume":"10","author":"Alvarez-Zarate","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2026.118276_b0125","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1182\/blood-2011-02-338020","article-title":"Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy","volume":"118","author":"Chao","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2026.118276_b0130","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-hodgkin lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2026.118276_b0135","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.3324\/haematol.2024.286864","article-title":"Dissecting CD47 expression in lymphoid neoplasms to inform precision immunotherapy with anti-CD47 phagocytic checkpoint blockade","volume":"110","author":"Marra","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.bcp.2026.118276_b0140","doi-asserted-by":"crossref","first-page":"203","DOI":"10.55730\/1300-0144.5958","article-title":"Does CD47 expression have prognostic significance in classical Hodgkin lymphoma?","volume":"55","author":"Kili\u00e7arslan","year":"2024","journal-title":"Turk. J. Med. Sci."},{"key":"10.1016\/j.bcp.2026.118276_b0145","doi-asserted-by":"crossref","first-page":"60892","DOI":"10.18632\/oncotarget.18492","article-title":"Anti-CD47 antibodies induce phagocytosis of live, malignant B cells by macrophages via the Fc domain, resulting in cell death by phagoptosis","volume":"8","author":"M\u00e9tayer","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2026.118276_b0150","doi-asserted-by":"crossref","unstructured":"H.R. Park, S.E. Kim, B. Keam, H. Chung, S.H. Seok, S. Kim, M. Kim, T.M. Kim, J. Doh, D.W. Kim, D.S. Heo, Blockade of CD47 enhances the antitumor effect of macrophages in renal cell carcinoma through trogocytosis, Sci. Rep. 2022 12:1 12 (2022) 12546-. https:\/\/doi.org\/10.1038\/s41598-022-16766-3.","DOI":"10.1038\/s41598-022-16766-3"},{"key":"10.1016\/j.bcp.2026.118276_b0155","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.3324\/haematol.2024.286208","article-title":"Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study","volume":"110","author":"Kim","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.bcp.2026.118276_b0160","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006567","article-title":"BYON4228 is a pan-allelic antagonistic SIRP\u03b1 antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRP\u03b3on T cells","volume":"11","author":"Van Helden","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bcp.2026.118276_b0165","unstructured":"Study Details | NCT06932952 | A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors | ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/study\/NCT06932952 (accessed March 28, 2026)."},{"key":"10.1016\/j.bcp.2026.118276_b0170","unstructured":"Byondis begins dosing in trial of BYON4228 for solid tumours, (n.d.). https:\/\/www.clinicaltrialsarena.com\/news\/byondis-byon4228-solid-tumours\/ (accessed March 28, 2026)."},{"key":"10.1016\/j.bcp.2026.118276_b0175","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/imr.12527","article-title":"The CD47-SIRP\u03b1 signaling axis as an innate immune checkpoint in cancer","volume":"276","author":"Matlung","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.bcp.2026.118276_b0180","doi-asserted-by":"crossref","first-page":"7795","DOI":"10.3390\/cimb46080462","article-title":"Phagocytosis checkpoints in glioblastoma: CD47 and beyond","volume":"46","author":"Afzal","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.bcp.2026.118276_b0185","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.3324\/haematol.2023.284795","article-title":"Blockade of the CD47\/SIRP\u03b1 checkpoint axis potentiates the macrophage-mediated antitumor efficacy of tafasitamab","volume":"109","author":"Biedermann","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.bcp.2026.118276_b0190","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/icb.2014.93","article-title":"Bispecific T-cell engagers for cancer immunotherapy","volume":"93","author":"Huehls","year":"2015","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.bcp.2026.118276_b0195","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.3390\/cancers16081580","article-title":"T-cell engagers\u2014the structure and functional principle and application in hematological Malignancies","volume":"16","author":"Cech","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bcp.2026.118276_b0200","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/17460441.2025.2522088","article-title":"The impact of CD3 affinity-attenuation on T cell engaging bispecific antibodies: is it really that simple?","volume":"20","author":"Abdelmotaleb","year":"2025","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.bcp.2026.118276_b0205","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133757","article-title":"Target arm affinities determine preclinical efficacy and safety of anti-HER2\/CD3 bispecific antibody","volume":"5","author":"Staflin","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.bcp.2026.118276_b0210","doi-asserted-by":"crossref","unstructured":"M. Wan, P.B. Kohli, S. Khan, H. Stephenson, R.A. Dave, Mechanistic modeling to inform T cell engager development for low copy targets, (2024). https:\/\/doi.org\/10.70534\/QSOL7421.","DOI":"10.70534\/QSOL7421"},{"key":"10.1016\/j.bcp.2026.118276_b0215","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.83659","article-title":"Population dynamics of immunological synapse formation induced by bispecific T cell engagers predict clinical pharmacodynamics and treatment resistance","volume":"12","author":"Liu","year":"2023","journal-title":"Elife"},{"key":"10.1016\/j.bcp.2026.118276_b0220","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2181016","article-title":"Strategies for clinical dose optimization of T cell-engaging therapies in oncology","volume":"15","author":"Ball","year":"2023","journal-title":"MAbs"},{"key":"10.1016\/j.bcp.2026.118276_b0225","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.118276_b0230","doi-asserted-by":"crossref","unstructured":"Mechanisms of CD8+ T cell exhaustion and its clinical significance in prognosis of anti-tumor therapies: A review, Int. Immunopharmacol. 159 (2025) 114843. https:\/\/doi.org\/10.1016\/J.INTIMP.2025.114843.","DOI":"10.1016\/j.intimp.2025.114843"},{"key":"10.1016\/j.bcp.2026.118276_b0235","article-title":"T cell exhaustion in cancer immunotherapy: heterogeneity, mechanisms, and therapeutic opportunities","volume":"13","author":"Yu","year":"2026","journal-title":"Adv. Sci."},{"key":"10.1016\/j.bcp.2026.118276_b0240","doi-asserted-by":"crossref","first-page":"12410","DOI":"10.1073\/pnas.1905675116","article-title":"TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion","volume":"116","author":"Seo","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2026.118276_b0245","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2026.118276_b0250","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1182\/blood-2024-211979","article-title":"Tumor intrinsic and antigen-independent resistance mechanisms to bispecific T cell engagers in multiple myeloma","volume":"144","author":"Lee","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2026.118276_b0255","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2026.118276_b0260","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/1078-0432.CCR-24-2247","article-title":"Clinical pharmacology of cytokine release syndrome with T-cell\u2013engaging bispecific antibodies: current insights and drug development strategies","volume":"31","author":"Radtke","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.118276_b0265","first-page":"1","article-title":"Bispecific T cell engagers for treatment-refractory autoimmune connective tissue diseases","volume":"2026","author":"D\u00fcsing","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2026.118276_b0270","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1038\/s41591-025-03937-8","article-title":"Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial","volume":"31","author":"Feng","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2026.118276_b0275","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/art.42415","article-title":"Efficacy and safety of ABBV-3373, a novel anti-tumor necrosis factor glucocorticoid receptor modulator antibody-drug conjugate, in adults with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a randomized, double-blind, active-contro\u2026","volume":"75","author":"Buttgereit","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.bcp.2026.118276_b0280","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.2169\/internalmedicine.4417-20","article-title":"Methotrexate-associated hodgkin lymphoma in a patient with rheumatoid arthritis successfully treated with brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine (BV+AVD)","volume":"59","author":"Sekiguchi","year":"2020","journal-title":"Intern. Med."},{"key":"10.1016\/j.bcp.2026.118276_b0285","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1016\/j.ymthe.2024.07.028","article-title":"T cell-redirecting therapies in hematological malignancies: current developments and novel strategies for improved targeting","volume":"32","author":"Anderson","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcp.2026.118276_b0290","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118276_b0295","doi-asserted-by":"crossref","unstructured":"V.A. Rybachuk, E.S. Evstratova, I.D. Klabukov, S.A. Ivanov, P. V. Shegai, A.D. Kaprin, D.S. Baranovsky, A Bright Future for Immunotherapy: CAR T-Cell Therapy Promises Revolutionary Changes, Healthbook TIMES Oncology Hematology 22 (2024) 2024. https:\/\/doi.org\/10.36000\/HBT.OH.2024.22.164.","DOI":"10.36000\/HBT.OH.2024.22.164"},{"key":"10.1016\/j.bcp.2026.118276_b0300","article-title":"Targeting B cells and plasma cells in autoimmune diseases: from established treatments to novel therapeutic approaches","volume":"53","author":"Merino-Vico","year":"2022","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.bcp.2026.118276_b0305","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar3909","article-title":"Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity","volume":"14","author":"Mei","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.bcp.2026.118276_b0310","article-title":"Targeting BCMA in multiple myeloma: a comprehensive review of immunotherapeutic strategies and clinical outcomes","volume":"33","author":"Chan","year":"2025","journal-title":"Mol. Therapy Oncol."},{"key":"10.1016\/j.bcp.2026.118276_b0315","doi-asserted-by":"crossref","DOI":"10.1002\/jha2.70062","article-title":"Teclistamab\u2010induced remission of chronic immune thrombocytopenia in a patient with multiple myeloma","volume":"6","author":"Quevedo-Salazar","year":"2025","journal-title":"Ejhaem"},{"key":"10.1016\/j.bcp.2026.118276_b0320","doi-asserted-by":"crossref","DOI":"10.1002\/art.70117","article-title":"Dual-targeting BCMA-CD19 CAR-T cell therapy in systemic lupus erythematosus: single-cell and immune repertoire analysis reveals mechanisms of immune reconstitution","author":"He","year":"2026","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.bcp.2026.118276_b0325","doi-asserted-by":"crossref","first-page":"7652","DOI":"10.3390\/ijms22147652","article-title":"Cytokine release syndrome associated with T-cell-based therapies for hematological malignancies: pathophysiology, clinical presentation, and treatment","volume":"22","author":"Cosenza","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.118276_b0330","unstructured":"Candid Therapeutics Plans to Initiate Multiple Phase 2 Studies Following Promising Clinical Data of T-cell Engagers in Autoimmune Diseases - BioSpace, (n.d.). https:\/\/www.biospace.com\/press-releases\/candid-therapeutics-plans-to-initiate-multiple-phase-2-studies-following-promising-clinical-data-of-t-cell-engagers-in-autoimmune-diseases (accessed May 2, 2026)."},{"key":"10.1016\/j.bcp.2026.118276_b0335","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35738","article-title":"Practical management of adverse events in patients receiving tarlatamab, a delta\u2010like ligand 3\u2013targeted bispecific T\u2010cell engager immunotherapy, for previously treated small cell lung cancer","volume":"131","author":"Sands","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2026.118276_b0340","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"New England J. Med."},{"key":"10.1016\/j.bcp.2026.118276_b0345","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1158\/1538-7445.AM2025-2130","article-title":"Abstract 2130: Optimization of tarlatamab step-up dosing regimen to mitigate cytokine release syndrome using quantitative systems pharmacology modeling","volume":"85","author":"Demin","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.118276_b0350","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/cpt.3361","article-title":"Dosing strategies and Quantitative clinical pharmacology for bispecific T-cell engagers development in oncology","volume":"116","author":"Elmeliegy","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2026.118276_b0355","doi-asserted-by":"crossref","first-page":"44","DOI":"10.32948\/ajpt.2025.04.15","article-title":"Pharmacokinetics and pharmacodynamics of tarlatamab, DLL3-targeted FDA-approved bispecific T-cell engager","author":"Ahmed Abdelmoaty","year":"2025","journal-title":"Asia-Pacific J. Pharmacother. Toxicol."},{"key":"10.1016\/j.bcp.2026.118276_b0360","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3390\/vaccines9101111","article-title":"Antibody-drug conjugates: functional principles and applications in oncology and beyond","volume":"9","author":"Theocharopoulos","year":"2021","journal-title":"Vaccines (Basel)."},{"key":"10.1016\/j.bcp.2026.118276_b0365","doi-asserted-by":"crossref","unstructured":"Z. Fu, S. Li, S. Han, C. Shi, Y. Zhang, Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy, Signal Transduction and Targeted Therapy 2022 7:1 7 (2022) 93-. https:\/\/doi.org\/10.1038\/s41392-022-00947-7.","DOI":"10.1038\/s41392-022-00947-7"},{"key":"10.1016\/j.bcp.2026.118276_b0370","doi-asserted-by":"crossref","unstructured":"A. Su, Y. Luo, C. Zhang, H. Duan, Linker-GPT: design of Antibody-drug conjugates linkers with molecular generators and reinforcement learning, Scientific Reports 2025 15:1 15 (2025) 20525-. https:\/\/doi.org\/10.1038\/s41598-025-05555-3.","DOI":"10.1038\/s41598-025-05555-3"},{"key":"10.1016\/j.bcp.2026.118276_b0375","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1208\/s12248-014-9710-8","article-title":"Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry","volume":"17","author":"McCombs","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.bcp.2026.118276_b0380","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","article-title":"Antibody\u2013drug conjugates: recent advances in linker chemistry","volume":"11","author":"Su","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bcp.2026.118276_b0385","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3390\/ijms17040561","article-title":"Linkers having a crucial role in antibody\u2013drug conjugates","volume":"17","author":"Lu","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.118276_b0390","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1021\/acs.bioconjchem.7b00062","article-title":"Effects of drug-antibody ratio on pharmacokinetics, biodistribution, efficacy, and tolerability of antibody-maytansinoid conjugates","volume":"28","author":"Sun","year":"2017","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.bcp.2026.118276_b0395","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jconrel.2021.07.041","article-title":"Polyethylene glycol-based linkers as hydrophilicity reservoir for antibody-drug conjugates","volume":"337","author":"Tedeschini","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bcp.2026.118276_b0400","doi-asserted-by":"crossref","unstructured":"S. Xu, Internalization, Trafficking, Intracellular processing and actions of antibody-drug conjugates, Pharmac. Res. 2015 32:11 32 (2015) 3577\u20133583. https:\/\/doi.org\/10.1007\/S11095-015-1729-8.","DOI":"10.1007\/s11095-015-1729-8"},{"key":"10.1016\/j.bcp.2026.118276_b0405","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1158\/1535-7163.MCT-17-0672","article-title":"Mechanistic modeling of antibody-drug conjugate internalization at the cellular level reveals inefficient processing steps","volume":"17","author":"Durbin","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2026.118276_b0410","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.2147\/DDDT.S135571","article-title":"Intracellular trafficking of new anticancer therapeutics: antibody\u2013drug conjugates","volume":"11","author":"Kalim","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bcp.2026.118276_b0415","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bcp.2026.118276_b0420","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.687926","article-title":"Linker design impacts antibody-drug conjugate pharmacokinetics and efficacy via modulating the stability and payload release efficiency","volume":"12","author":"Su","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118276_b0425","doi-asserted-by":"crossref","first-page":"11761","DOI":"10.3390\/ijms262311761","article-title":"CD74-targeting antibody\u2013drug conjugate enhances immunosuppression of glucocorticoid in systemic lupus erythematosus","volume":"26","author":"Du","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.118276_b0430","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.add8936","article-title":"An anti\u2013TNF\u2013glucocorticoid receptor modulator antibody-drug conjugate is efficacious against immune-mediated inflammatory diseases","volume":"16","author":"McPherson","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bcp.2026.118276_b0435","unstructured":"Study Details | NCT03823391 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA) | ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/study\/NCT03823391 (accessed May 4, 2026)."},{"key":"10.1016\/j.bcp.2026.118276_b0440","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/annrheumdis-2021-eular.2213","article-title":"POS0365 anti-tnf glucocorticoid receptor modulator antibody drug conjugate for the treatment of autoimmune diseases","volume":"80","author":"Stoffel","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2026.118276_b0445","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40259-017-0254-1","article-title":"Recent developments in ADC technology: preclinical studies signal future clinical trends","volume":"31","author":"Drake","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.bcp.2026.118276_b0450","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1087986","article-title":"JAK inhibitors differentially modulate B cell activation, maturation and function: a comparative analysis of five JAK inhibitors in an in-vitro B cell differentiation model and in patients withrheumatoid arthritis","volume":"14","author":"Frede","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118276_b0455","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4161\/mabs.20230","article-title":"Brentuximab vedotin","volume":"4","author":"Van De Donk","year":"2012","journal-title":"MAbs"},{"key":"10.1016\/j.bcp.2026.118276_b0460","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/2040620712443076","article-title":"Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma","volume":"3","author":"Vaklavas","year":"2012","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.bcp.2026.118276_b0465","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/729654","article-title":"Characterization of CD30\/CD30L+ Cells in peripheral blood and synovial fluid of patients with rheumatoid arthritis","volume":"2015","author":"Barbieri","year":"2015","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.bcp.2026.118276_b0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117576","article-title":"Advances and challenges in immunosuppressive antibody drug conjugates","volume":"291","author":"Yaseen","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118276_b0475","first-page":"34","article-title":"The next frontier in antibody-drug conjugates: challenges and opportunities in cancer and autoimmune therapy","volume":"8","author":"Zhou","year":"2025","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.bcp.2026.118276_b0480","doi-asserted-by":"crossref","unstructured":"J. Liang, X. Zhou, L. Jiang, J. Liang, X. Zhou, L. Jiang, Targeting Inflammatory Cytokines in Autoimmune Diseases: Mechanisms and Therapeutic Advances with Antibody-Based Therapies, Https:\/\/Www.Sciltp.Com\/Journals\/Hm\/Articles\/2508001125 2 (2025) 8. https:\/\/doi.org\/10.53941\/HM.2025.100031.","DOI":"10.53941\/hm.2025.100031"},{"key":"10.1016\/j.bcp.2026.118276_b0485","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3390\/curroncol32050261","article-title":"ADCs and TCE in SCLC Therapy: the beginning of a New Era?","volume":"32","author":"Muscolino","year":"2025","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.bcp.2026.118276_b0490","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20251652","article-title":"T cell engagers emerge as a compelling therapeutic modality","volume":"223","author":"Baeuerle","year":"2026","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcp.2026.118276_b0495","first-page":"58","article-title":"Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy","volume":"9","author":"Kang","year":"2026","journal-title":"Antib. Ther."},{"key":"10.1016\/j.bcp.2026.118276_b0500","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s00210-025-04425-z","article-title":"CAR T cell therapy efficacy and safety in SLE: a systematic review and pooled analysis of 47 patients across 10 studies","volume":"399","author":"Sayed","year":"2025","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118276_b0505","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3390\/cancers16040827","article-title":"Innovations in antibody-drug conjugate (ADC) in the treatment of lymphoma","volume":"16","author":"Al Sbihi","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bcp.2026.118276_b0510","article-title":"Another power of antibody-drug conjugates: immunomodulatory effect and clinical applications","volume":"16","author":"Shi","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118276_b0515","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1158\/1538-7445.AM2014-3694","article-title":"Abstract 3694: Relationship between in vivo antitumor activity of ADC and payload release in preclinical models","volume":"74","author":"Li","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.118276_b0520","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-15-1795","article-title":"Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models","volume":"76","author":"Li","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.118276_b0525","doi-asserted-by":"crossref","unstructured":"A.H. Staudacher, M.P. Brown, Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?, British Journal of Cancer 2017 117:12 117 (2017) 1736\u20131742. https:\/\/doi.org\/10.1038\/bjc.2017.367.","DOI":"10.1038\/bjc.2017.367"},{"key":"10.1016\/j.bcp.2026.118276_b0530","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1012839","article-title":"Mechanistic modeling suggests stroma-targeting antibody-drug conjugates as an alternative to cancer-targeting in cases of heterogeneous target exspression","volume":"21","author":"Wood","year":"2025","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.bcp.2026.118276_b0535","doi-asserted-by":"crossref","unstructured":"G. Albayrak, P.K.T. Wan, K. Fisher, L.W. Seymour, T cell engagers: expanding horizons in oncology and beyond, British Journal of Cancer 2025 133:9 133 (2025) 1241\u20131249. https:\/\/doi.org\/10.1038\/s41416-025-03125-y.","DOI":"10.1038\/s41416-025-03125-y"},{"key":"10.1016\/j.bcp.2026.118276_b0540","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.118276_b0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107778","article-title":"Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates","volume":"26","author":"Fu","year":"2023","journal-title":"Iscience"},{"key":"10.1016\/j.bcp.2026.118276_b0550","doi-asserted-by":"crossref","unstructured":"Y. Chen, X. Ren, Y. Dai, Y. Wang, Pharmacovigilance study of the association between peripheral neuropathy and antibody\u2013drug conjugates using the FDA adverse event reporting system, Scientific Reports 2024 14:1 14 (2024) 21386-. https:\/\/doi.org\/10.1038\/s41598-024-71977-0.","DOI":"10.1038\/s41598-024-71977-0"},{"key":"10.1016\/j.bcp.2026.118276_b0555","doi-asserted-by":"crossref","first-page":"6013","DOI":"10.1097\/MS9.0000000000001375","article-title":"Toxicities of CAR T-cell therapy: a review of current literature","volume":"85","author":"Asghar","year":"2023","journal-title":"Ann. Med. Surg."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226006155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226006155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:22:05Z","timestamp":1791908525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226006155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":111,"alternative-id":["S0006295226006155"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118276","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond immune checkpoint blockade: T cell engagers and antibody-drug conjugates in cancer and autoimmune disease","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118276","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118276"}}